Trials / Active Not Recruiting
Active Not RecruitingNCT04122976
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 805 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darolutamide(Nubeqa, BAY1841788) | The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information. |
Timeline
- Start date
- 2020-01-30
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2019-10-10
- Last updated
- 2026-04-14
Locations
41 sites across 17 countries: United States, Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Denmark, France, Germany, Greece, Italy, Japan, Russia, Spain, Taiwan
Source: ClinicalTrials.gov record NCT04122976. Inclusion in this directory is not an endorsement.